Soft-tissue tumors are defined as neoplasms derived from nonepithelial extraskeletal tissue of the body excluding the reticuloendothelial system, neuroglial cells, and supporting tissue of various parenchymal organs (Enzinger and Weiss, Soft tissue tumors, St. Louis, Mosby:1–13, 1983). Representative soft tissues from which neoplasms commonly arise are the muscles, fat, skin, blood and lymph vessels, lymph nodes, and nerve fibers. A survey of 1331 consecutive cases of benign soft-tissue tumors showed lipoma to be the most common, accounting for nearly half of the entire series, and fibrocystic tumors and hemangioma were relatively common (Myhre-Jensen, Acta Orthop Scand 52:287–293, 1981). Among sarcomas, liposarcoma ranked first, and fibrosarcoma, rhabdomyosarcoma, unclassified sarcomas, leiomyosarcoma, and synovial sarcoma followed in decreasing order. The prevalence rate of sarcoma was estimated to be approximately 1% of all malignant tumors, and the benign to malignant mesenchymal tumor ratio was 100:1 in a hospital population (Enzinger and Weiss, Soft tissue tumors, St. Louis, Mosby:1–13, 1983).
This is a preview of subscription content, log in to check access.
Anvar MD, Khiabani HZ, Nesland JM et al (2000) Vascular and stromal features in the skin of the lower limb in patients with chronic limb ischemia (CLI) and oedema. Eur J Vasc Endovasc Surg 20:125–131CrossRefPubMedGoogle Scholar
Beres RA, Patel N, Krasnow AZ et al (1991) Concentration of Tc-99 m MDP in ovarian carcinoma and its soft tissue metastases. Clin Nucl Med 16:550–552CrossRefPubMedGoogle Scholar
Burke W, Rubens MB (1993) Uptake of technetium-99 m methylene diphosphonate by a pulmonary hamartoma/mesenchymoma. Br J Radiol 66:74–76CrossRefPubMedGoogle Scholar
Cory DA, Siddiqui AR, Cohen MD (1987) Uptake of technetium 99 m MDP by hepatoblastoma. Eur J Nucl Med 12:546–547CrossRefPubMedGoogle Scholar
Enzinger FM, Weiss SW (1983) General considerations. In: Soft tissue tumors. Mosby, St. Louis, pp 1–13Google Scholar
Garty I, Rosen G, Risescu J (1984) Extraosseous 99mTc-MDP uptake in mediastinal thyroid goiter: two case reports. Eur J Nucl Med 9:521–524CrossRefPubMedGoogle Scholar
McKenna D, Igbal A, O’Keeffe D (2004) Tc-99 m methylene diphosphonate uptake in a primary lung cancer. Clin Nucl Med 29:723–724CrossRefGoogle Scholar
Montes TC, Munoz C, Rivero JI et al (1999) Uptake of Tc-99 m sestamibi and Tc-99 m MDP in anaplastic carcinoma of the thyroid (nondiagnostic CT and ultrasound scans). Clin Nucl Med 24:355–356CrossRefPubMedGoogle Scholar
Murphy MD, Fairbairn KJ, Parman LM et al (1995) From the archives of the AFIP. Musculoskeletal angiomatous lesions: radiographic-pathology correlation. Radiographics 15:893–917CrossRefGoogle Scholar
Myhre-Jensen O (1981) A consecutive 7-year series of 1331 benign tissue tumours. Clinicopathologic data. Comparison with sarcomas. Acta Orthop Scand 52:287–293CrossRefPubMedGoogle Scholar
Piccolo S, Lastoria S, Muto P et al (1997) Scintimammography with 99mTc-MDP in the detection of primary breast cancer. Q J Nucl Med 41:225–230PubMedGoogle Scholar
Pickhardt PJ, McDermott M (1997) Intense uptake of technetium-99 m-MDP in primary breast adenocarcinoma with sarcomatoid metaplasia. J Nucl Med 38:528–530PubMedGoogle Scholar
Riedy G, Adler L (2000) Tc-99 m MDP thyroid uptake in a patient with a large nontoxic goiter. Clin Nucl Med 25:929–930CrossRefPubMedGoogle Scholar